Understanding the Latest Therapeutic Advances in Multiple Myeloma: Expert Guidance and Implications for Treatment Decisions

Watch this on-demand webcast from our live meeting series on the latest clinical data for treating your patients with multiple myeloma and use the downloadable slides in your own presentations.
Shaji Kumar, MD
Program Director
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: May 15, 2019 Expiration: May 14, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate timely systemic treatment for appropriate patients based on newly revised multiple myeloma diagnosis and staging criteria
  • Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
  • Identify ongoing trials of investigational approaches in the treatment of multiple myeloma to aid referral of patients for study participation

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Shaji Kumar, MD

Department of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD has disclosed that he has consulted with payment to Mayo Clinic from AbbVie, Amgen, Celgene, Genentech, Janssen, Kite, MedImmune, Merck, and Takeda; has received honorarium or consultation fees from Adaptive Biotechnologies, Dr. Reddy’s Laboratory, Oncopeptides, and Ono Pharmaceuticals; and received funds to Mayo Clinic for research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Sanofi, and Takeda.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD has no real or apparent conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with multiple myeloma.

Goal

The goal of this activity is to improve participants’ competence to provide optimal care for patients with multiple myeloma.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-19-056-H01-P. This program is designated for up to 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit.

Type of Activity Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 15, 2019, through May 14, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Dr. Jacqueline Barrientos shares her experiences managing patients with CLL during the COVID-19 pandemic in NYC and offers recommendations, from CCO

Jacqueline Barrientos, MD, MS Released: August 11, 2020

Downloadable summary slideset with a quick summary of the current treatment algorithm for CLL, from Clinical Care Options.

Farrukh T. Awan, MD Ian W. Flinn, MD, PhD Released: August 5, 2020

John M. Burke, MD Released: August 4, 2020

Expert-authored commentary with insight on the latest advances in the treatment of patients with FLT3-positive AML from CCO

Naval G. Daver, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: July 31, 2020 Expired: July 30, 2021
Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
AbbVie
Amgen
Celgene Corporation
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?